WBA - Healthcare Champions Kick Off 2024 | Benzinga
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly marketing as many as five products by 2026. Merck & CO Inc (NYSE: MRK) shares also rose 7.3% this year so far with the pharma giant announcing it is kicking off its phase 3 trial for four of its investigational candidates from its diverse and promising hematology and oncology pipeline.
2023 Was A Dismal For Moderna, But Don’t Dismiss The Covid-19 Star Just Yet
During 2023, Moderna had only one commercially available product- the Covid-19 shot, in a post-Covid era. But Moderna is working on its pipeline, with potential product launches over the next 12 to 18 months promising to turn things around in 2025. Along with its experimental vaccine that aims to protect older adults from respiratory syncytial virus and another experimental flu vaccine that could also win approval this year or in 2025, Moderna is developing a personalized ...